Previous retrospective studies reported prostate cancer RRs of 2-6 and absolute risks of 17%-31% by age 80 years for BRCA2 carriers (Data Supplement).2,5,6,8,14-17 Our estimated absolute risk by age 85 years was 33%, lower than the recently reported prospective estimate of 60% by Nyberg et al.32 However, after adjusting for possible increased prostate-specific antigen screening effects in the prospective study, their estimate was 41% (95% CI, 22 to 59), consistent with our estimate. This evidence concerns the gene BRCA2 and prostate cancer.